We are live on ! Find out more
BLRX icon

BioLineRX

30 hedge funds and large institutions have $16.3M invested in BioLineRX in 2019 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

212% more capital inflows, than outflows

Capital inflows: $1.47M | Capital outflows: $471K

0.26% more ownership

Funds ownership: 5.02% → 5.29% (+0.26%)

9% less funds holding

Funds holding: 33 → 30 (-3)

29% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 7

33% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 6

Holders
30
Holders Change
-3
Holders Change %
-9.09%
% of All Funds
0.65%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
5
Reduced
7
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

BLRX Hedge Fund Activity: Q1 2019 in Review

30 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q1 2019, worth a combined $16.3M — up 3.4% from $15.7M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of BLRX and 4 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 5 added.

The largest buyer was Senvest Management, adding an estimated $1.32M. The largest seller was Fosun International, cutting an estimated $304K.

  • 30 institutional investors held BioLineRX (BLRX) as of Q1 2019, down from 33 in Q4 2018.
  • Funds reported $16.3M of BioLineRX stock for Q1 2019, up 3.4% quarter-over-quarter.
  • 4 funds opened new BioLineRX positions in Q1 2019 and 6 closed out, a net change of -2 holders.
  • The largest BioLineRX buyer in Q1 2019 was Senvest Management, an estimated $1.32M added.
  • The largest BioLineRX seller in Q1 2019 was Fosun International, an estimated $304K sold.

Based on aggregated 13F filings for Q1 2019.